Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus

Scavenger receptor class B type 1 (SR-B1) and low-density lipoprotein receptor (LDLR) are known to be involved in entry of hepatitis C virus (HCV), but their precise roles and their interplay are not fully understood. In this study, deficiency of both SR-B1 and LDLR in Huh7 cells was shown to impair the entry of HCV more strongly than deficiency of either SR-B1 or LDLR alone. In addition, exogenous expression of not only SR-B1 and LDLR but also very low-density lipoprotein receptor (VLDLR) rescued HCV entry in the SR-B1 and LDLR double-knockout cells, suggesting that VLDLR has similar roles in HCV entry. VLDLR is a lipoprotein receptor, but the level of its hepatic expression was lower than those of SR-B1 and LDLR. Moreover, expression of mutant lipoprotein receptors incapable of binding to or uptake of lipid resulted in no or slight enhancement of HCV entry in the double-knockout cells, suggesting that binding and/or uptake activities of lipid by lipoprotein receptors are essential for HCV entry. In addition, rescue of infectivity in the double-knockout cells by the expression of the lipoprotein receptors was not observed following infection with pseudotype particles bearing HCV envelope proteins produced in non-hepatic cells, suggesting that lipoproteins associated with HCV particles participate in the entry through their interaction with lipoprotein receptors. Buoyant density gradient analysis revealed that HCV utilizes these lipoprotein receptors in a manner dependent on the lipoproteins associated with HCV particles. Collectively, these results suggest that lipoprotein receptors redundantly participate in the entry of HCV.

[1]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[2]  R. Cortese,et al.  Successful anti‐scavenger receptor class B type I (SR‐BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR‐BI‐targeting agents , 2014, Hepatology.

[3]  J. Suvarna,et al.  Serum lipid profile: a predictor of clinical outcome in dengue infection , 2009, Tropical medicine & international health : TM & IH.

[4]  M. Lai,et al.  Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III , 2012, Gut.

[5]  D. Sahoo,et al.  Functional Characterization of Newly-Discovered Mutations in Human SR-BI , 2012, PloS one.

[6]  Charles M. Rice,et al.  Role of SR-BI in HCV entry: kinetics and molecular determinants , 2009 .

[7]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[8]  S. Emerson,et al.  Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus , 2008, Proceedings of the National Academy of Sciences.

[9]  J. McKeating,et al.  Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies , 2007, Hepatology.

[10]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[11]  Ursula Andréo,et al.  The interaction of natural hepatitis C virus with human scavenger receptor SR‐BI/Cla1 is mediated by ApoB‐containing lipoproteins , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  P. André,et al.  Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles , 2002, Journal of Virology.

[13]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[14]  C. Rice,et al.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells , 2009, The Journal of general virology.

[15]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[16]  R. Cortese,et al.  High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein , 2007, Journal of Virology.

[17]  J. Pawlotsky,et al.  Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection , 2015, Hepatology.

[18]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[19]  M. J. Evans,et al.  Hepatitis C virus host cell entry. , 2012, Current opinion in virology.

[20]  D. Lavillette,et al.  The Tight Junction Proteins Claudin-1, -6, and -9 Are Entry Cofactors for Hepatitis C Virus , 2008, Journal of Virology.

[21]  R. Cortese,et al.  Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor* , 2003, Journal of Biological Chemistry.

[22]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[23]  William J. Rice,et al.  Ultrastructural analysis of hepatitis C virus particles , 2013, Proceedings of the National Academy of Sciences.

[24]  S. Wünschmann,et al.  Characterization of Hepatitis C Virus (HCV) and HCV E2 Interactions with CD81 and the Low-Density Lipoprotein Receptor , 2000, Journal of Virology.

[25]  Lawrence Corey,et al.  Dynamics of hepatitis C virus replication in human liver. , 2003, The American journal of pathology.

[26]  D. Russell,et al.  Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. , 1989, The Journal of biological chemistry.

[27]  F. Chisari,et al.  Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver , 2014, Hepatology.

[28]  J. McKeating,et al.  Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. , 2011, Journal of hepatology.

[29]  Lars Kaderali,et al.  Apolipoprotein E Codetermines Tissue Tropism of Hepatitis C Virus and Is Crucial for Viral Cell-to-Cell Transmission by Contributing to a Postenvelopment Step of Assembly , 2013, Journal of Virology.

[30]  G. Church,et al.  Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. , 2011, Nature biotechnology.

[31]  K. Shimotohno,et al.  Hepatitis C virus utilizes VLDLR as a novel entry pathway , 2015, Proceedings of the National Academy of Sciences.

[32]  Marco M. Domingues,et al.  Understanding dengue virus capsid protein disordered N-Terminus and pep14-23-based inhibition. , 2015, ACS chemical biology.

[33]  Jieyun Jiang,et al.  Human Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture , 2007, Journal of Virology.

[34]  Christopher T. Jones,et al.  A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo , 2012, Hepatology.

[35]  T. Hu,et al.  Role of hepatitis C virus substitutions and interleukin‐28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response‐guided therapy , 2013, Journal of viral hepatitis.

[36]  Olivier Poch,et al.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.

[37]  Charles M. Rice,et al.  Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.

[38]  Ralf Bartenschlager,et al.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.

[39]  Y. Maehara,et al.  Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus , 2012, Journal of Virology.

[40]  Ralf Bartenschlager,et al.  Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps* , 2012, The Journal of Biological Chemistry.

[41]  Christopher T. Jones,et al.  Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission , 2013, Journal of Virology.

[42]  T. Dragic,et al.  Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry , 2006, Journal of Virology.

[43]  V. Agnello,et al.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Hongwei Li,et al.  Human Apolipoprotein A-I Is Associated with Dengue Virus and Enhances Virus Infection through SR-BI , 2013, PloS one.

[45]  L. Kaderali,et al.  Isolate‐dependent use of claudins for cell entry by hepatitis C virus , 2014, Hepatology.

[46]  A. Folgori,et al.  Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. , 2012, Journal of hepatology.

[47]  M. J. Evans,et al.  Temporal Analysis of Hepatitis C Virus Cell Entry with Occludin Directed Blocking Antibodies , 2013, PLoS pathogens.

[48]  R. D. del Ángel,et al.  The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. , 2013, Virology.

[49]  Y. Shimizu,et al.  Infectivity of Hepatitis C Virus Is Influenced by Association with Apolipoprotein E Isoforms , 2010, Journal of Virology.

[50]  Sangeeta N. Bhatia,et al.  Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system , 2010, Nature Biotechnology.

[51]  M. Imamura,et al.  Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor , 2011, Nature Medicine.

[52]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[53]  J. V. D. van der Meer,et al.  Changes in the plasma lipid profile as a potential predictor of clinical outcome in dengue hemorrhagic fever. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  Emily M. Lee,et al.  Cell Death-Inducing DFFA-Like Effector b Is Required for Hepatitis C Virus Entry into Hepatocytes , 2014, Journal of Virology.

[55]  M. Hayden,et al.  Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans , 2011, Clinical genetics.

[56]  H. Wedemeyer,et al.  Natural history of acute and chronic hepatitis C. , 2012, Best practice & research. Clinical gastroenterology.

[57]  Charles M. Rice,et al.  Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants , 2009, Journal of Virology.

[58]  M. Ronaghi,et al.  Ontology-Based Meta-Analysis of Global Collections of High-Throughput Public Data , 2010, PloS one.

[59]  Xijun Song,et al.  Claudin-6 and Claudin-9 Function as Additional Coreceptors for Hepatitis C Virus , 2007, Journal of Virology.

[60]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[61]  T. Asahara,et al.  Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.

[62]  S. Emerson,et al.  Apolipoprotein C1 Association with Hepatitis C Virus , 2008, Journal of Virology.

[63]  Johan Neyts,et al.  The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination , 2013, Hepatology.

[64]  F. Chisari,et al.  Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion , 2007, Journal of Virology.

[65]  M. Gale,et al.  Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. , 2009, Virology.

[66]  V. Johnson,et al.  Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. , 2014, The Journal of infectious diseases.

[67]  A. Burt,et al.  Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients , 2006, Journal of Virology.

[68]  K. Shimotohno,et al.  Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus , 2015, Journal of Virology.